Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H1 2018

Summary

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade.

LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Preclinical and Discovery stages are 1, 7 and 1 respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Oncology and Ophthalmology which include indications Obesity, Alzheimer's Disease, Lipodystrophy, Type 2 Diabetes, Acquired Generalized Lipodystrophy (Lawrence Syndrome), Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome), Breast Cancer, Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome) and Type 1 Diabetes (Juvenile Diabetes).

The latest report Leptin Receptor - Pipeline Review, H1 2018, outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
- The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various